Beam Therapeutics Inc.
BEAM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $3 | $5 |
| - Cash | $0 | $0 | $0 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $2 | $3 | $4 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -83.2% | 520% | 17.5% | – |
| Gross Profit | -$0 | $0 | -$0 | -$0 |
| % Margin | -478.7% | 100% | -411.5% | -347.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -619.7% | -38.9% | -532.4% | -443.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -593.1% | -35.1% | -474.5% | -714.9% |
| EPS Diluted | -4.58 | -1.72 | -4.13 | -5.77 |
| % Growth | -166.3% | 58.4% | 28.4% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |